Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407

The global phase III KEYNOTE‐407 (NCT02775435) trial showed that pembrolizumab plus chemotherapy prolonged overall and progression‐free survival (OS/PFS) versus placebo plus chemotherapy in patients with metastatic squamous non‐small‐cell lung cancer (NSCLC). We present outcomes of patients from Jap...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Shunichi, Tanaka, Kentaro, Imamura, Fumio, Yamamoto, Nobuyuki, Nishio, Makoto, Okishio, Kyoichi, Hirashima, Tomonori, Tanaka, Hiroshi, Fukuhara, Tatsuro, Nakahara, Yasuharu, Kurata, Takayasu, Katakami, Nobuyuki, Okada, Morihito, Horinouchi, Hidehito, Udagawa, Hibiki, Kasahara, Kazuo, Satouchi, Miyako, Saka, Hideo, Tokito, Takaaki, Hosomi, Yukio, Aoe, Keisuke, Kishi, Kazuma, Ohashi, Kadoaki, Yokoyama, Takuma, Adachi, Noriaki, Noguchi, Kazuo, Schwarzenberger, Paul, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394135/
https://www.ncbi.nlm.nih.gov/pubmed/37183528
http://dx.doi.org/10.1111/cas.15816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394135/
https://www.ncbi.nlm.nih.gov/pubmed/37183528
http://dx.doi.org/10.1111/cas.15816

Ejemplares similares